Coherus BioSciences

Intas Pharmaceuticals' U.S. division, Accord BioPharma, acquires Coherus BioSciences' UDENYCA® biosimilar to expand its portfolio. Intas also partners with Xbrane for a nivolumab biosimilar, aiming for launch post-patent expiration.

Chinese pharmaceutical and bio industry's technology exports surged to 80 cases in 2022, nearly doubling from 41 in 2021. Major deals include Merck's $9.475 billion investment in Kelun's ADC technology and J&J's CAR-T therapy 'Carvykti' developed with Legend Biotech. FDA approvals for Chinese drugs like Junshi Biosciences' 'Toripalimab' and Bio-Thera Solutions' 'Avitinib' highlight China's growing influence in global bio market.

Dr. Reddy’s Laboratories launched Zytorvi, a biosimilar of Coherus BioSciences’ Loqtorzi, in India for treating recurrent or metastatic nasopharyngeal carcinoma. Loqtorzi, an anti-PD-1 monoclonal antibody, is the first FDA-approved immuno-oncology drug for this indication, also approved in the EU and U.K. Dr. Reddy’s secured exclusive rights to develop and market Toripalimab in 21 countries, including India, through a partnership with Junshi Biosciences.

Coherus BioSciences announces Dr. Theresa LaVallee, Chief Development Officer, will participate in the 2024 Citi Global Healthcare Conference's Novel Mechanisms in Oncology Panel on Dec 3, 2024, at 3:15 p.m. ET. The discussion will be webcasted via the Coherus website.

Formycon reports nine-month results for 2024, highlighting product approvals for FYB202 in the USA and Europe, the start of clinical development for Keytruda® biosimilar FYB206, and the initiation of FYB210 development. Financial results reflect successful business performance, confirming guidance.

UK MHRA approves toripalimab (Loqtorzi) for frontline treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC), supported by phase 3 trials showing improved survival and response rates.

Neutropenia treatment market to reach USD 20.8 billion by 2032, driven by cancer prevalence and chemotherapy-induced neutropenia. Rising R&D leads to new therapies like G-CSFs and oral treatments. Idiopathic neutropenia and APAC market growth are significant. Key players include Amgen, Pfizer, and Teva.

Articles from various sources reference studies and reports published in The American Journal of Managed Care, covering topics such as machine learning in healthcare, Medicare Advantage turnover, affordability of GLP-1 drugs, AI-powered robots in respiratory care, updated colonoscopy guidelines, and biosimilar partnerships.